Swiss Capital Markets Stock News

In March 2026, Sonova Holding AG announced plans to sell its Consumer Hearing business, which markets premium audio products under the Sennheiser brand, and said it will classify this unit as discontinued operations in its 2026 financial results. The move highlights a sharpened focus on Sonova’s core innovation areas in hearing care, while it simultaneously explores geo-targeted retail acquisitions to reshape its portfolio. Next, we’ll examine how exiting the Sennheiser-branded Consumer...

Implenia (SWX:IMPN) recently reported new building contracts in Switzerland and Germany worth more than CHF 310 million. These cover residential, commercial and institutional projects scheduled between 2026 and 2028, with a strong emphasis on timber and climate-friendly construction. See our latest analysis for Implenia. Despite the new CHF 310 million contract wins, Implenia’s share price has a 30 day share price return of 10.1% and a year to date share price return of 18%. At the same time,...

Amrize (SWX:AMRZ) has appointed Baris Oran as Chief Financial Officer and member of the Executive Committee. The appointment is effective April 1 and represents a major change in the company’s top leadership team. Oran brings international financial leadership experience from prior CFO and executive roles at large multinational companies, including GXO Logistics. For investors watching Amrize (SWX:AMRZ), a change in the CFO seat can matter as much as product launches or new contracts. The...

Recent performance snapshot Partners Group Holding (SWX:PGHN) has drawn attention after a recent share price move, with the stock up 2.6% over the past day and 4.6% over the past week on the Swiss market. See our latest analysis for Partners Group Holding. That short term momentum contrasts with a 90 day share price return of an 11.62% decline and a 1 year total shareholder return showing a 27.63% loss, while the 3 year total shareholder return of 16.27% points to a stronger longer run...

UBS Group (SWX:UBSG) is back in focus after reports that senior Swiss lawmakers plan to soften proposed capital rules, easing earlier concerns that a sharp regulatory shift might pressure the bank’s operating footprint. See our latest analysis for UBS Group. At a share price of CHF31.56, UBS Group’s recent 2.7% 1 day and 4.6% 7 day share price returns sit against a weaker 90 day share price return of 14.6% and a much stronger 5 year total shareholder return of 141.4%. This suggests that near...

In March 2026, Julius Bär Gruppe AG announced it would exercise its option to redeem all outstanding Perpetual Tier 1 Subordinated Bonds (ISIN: XS2238020445), originally issued on 8 October 2020 with a 4.875% coupon and an aggregate nominal amount of US$350,000,000, at par plus accrued interest on the first call date of 8 April 2026. This early redemption under condition 3(c) highlights Julius Bär’s active approach to capital structure management, reflecting how it balances funding costs,...

Why DKSH Holding (SWX:DKSH) is back on income investors’ radar DKSH Holding (SWX:DKSH) caught fresh attention after its March 27 annual general meeting, where shareholders backed a 6.4% dividend increase to CHF 2.50 per share and elected two new board members. See our latest analysis for DKSH Holding. Despite the dividend increase and board refresh, DKSH Holding's CHF58.0 share price sits below where it was a year ago, with a 1-year total shareholder return decline of 10.83%, while a modest...

Novartis (SWX:NOVN) is back in focus after recent share price moves, with the stock showing mixed returns over the past month and past 3 months. This puts current valuation and fundamentals under the spotlight for investors. See our latest analysis for Novartis. The recent share price pullback, with a 1 month share price return of a 5.5% decline after a stronger 3 month share price return of 12%, comes against a backdrop of stronger long term total shareholder returns of 30.7% over 1 year and...

Lonza recently published its 2025 Annual and Sustainability Reports, called its 2026 Annual General Meeting for 8 May in Basel, and proposed a 25% dividend increase alongside a broad board refresh. The nomination of former Eli Lilly executive Stephen Fry and other new directors with healthcare, automation, AI and biopharma expertise underscores Lonza’s emphasis on governance quality and future-focused capabilities in its core CDMO business. We’ll now explore how Lonza’s planned 25% dividend...

Conference update and disruption disclosure VAT Group (SWX:VACN) used its SEMICON China 2026 appearance in Shanghai to spotlight its role in chip production equipment, while also highlighting that war related supply disruptions are weighing on its near term sales. See our latest analysis for VAT Group. That supply shock message appears to have cooled sentiment in the short term, with a 7 day share price return of 6.53% and a 30 day share price return of 11.10%. At the same time, the 90 day...

MCH Group AG ( VTX:MCHN ) just released a solid earnings report, and the stock displayed some strength. However, we...

Amid ongoing geopolitical tensions and fluctuating energy prices, European markets have experienced mixed performance, with the pan-European STOXX Europe 600 Index seeing a modest gain. In this uncertain environment, identifying stocks trading below their estimated fair value can present potential opportunities for investors seeking to capitalize on market inefficiencies.

Investors signalled that they were pleased with ORIOR AG's ( VTX:ORON ) most recent earnings report. According to our...

BKW (SWX:BKW) is back in focus after announcing that Philipp Hänggi will hand over his role as Executive Vice President, Energy Production, to Margarita Aleksieva, whose background is rooted in wind and solar operations. See our latest analysis for BKW. At a share price of CHF156.2, BKW has a 7 day share price return of 3.79% and a 30 day share price return of 3.17%. The 1 year total shareholder return of 2.09% sits alongside a 5 year total shareholder return of 68.02%, suggesting longer term...

In March 2026, Emmi AG was removed from the FTSE All-World Index, altering its representation in a widely followed global equity benchmark. This index removal may influence how index-tracking institutional investors allocate capital to Emmi, potentially reshaping its visibility in global portfolios. Next, we will examine how Emmi's removal from the FTSE All-World Index may influence its investment narrative and investor perception. Capitalize on the AI infrastructure supercycle with our...

SoftwareOne Holding (SWX:SWON) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 486.6 million and basic EPS of CHF 0.07, while the trailing twelve months show revenue of CHF 1.2 billion and basic EPS of CHF 0.13. Over the past reported periods, revenue has moved from CHF 529.2 million and EPS of CHF 0.18 in the first half of 2024 to CHF 486.2 million and an EPS loss of CHF 0.19 in the second half of 2024, before landing at the latest CHF 486.6 million and CHF...

Swissquote Group Holding SA has released its full-year 2025 results, reporting net income of CHF 366.39 million and basic earnings per share from continuing operations of CHF 24.49, alongside declaring an annual dividend of CHF 7.40 per share payable in May 2026. The combination of higher earnings and a larger cash payout suggests management is comfortable sharing more of the company’s profitability with shareholders. We’ll now explore how Swissquote’s strong 2025 earnings and increased CHF...

Why Idorsia’s latest pediatric insomnia data matters for shareholders Idorsia (SWX:IDIA) shares have moved after the company reported positive top-line Phase 2 results for daridorexant in children with insomnia disorder, including patients with neurodevelopmental conditions, and outlined plans to engage regulators on next steps. The trial used a 2 week treatment period and showed a statistically significant, dose-dependent improvement in total sleep time from baseline on Day 1, along with...

Julius Bär Gruppe (SWX:BAER) has drawn attention after announcing plans to redeem its USD 350 million Perpetual Tier 1 subordinated bonds at par plus accrued interest on the first call date in April 2026. See our latest analysis for Julius Bär Gruppe. The refinancing decision comes after a period where the share price has softened, with a 30 day share price return of a 12.04% decline and a year to date share price return of a 12.28% decline. Longer term total shareholder returns over three...

Novartis (SWX:NOVN) agreed to acquire Excellergy, a biotech focused on anti IgE therapies for allergic diseases, including food allergies. The company reported positive final two year Phase III results for Fabhalta in IgA nephropathy, indicating slower kidney function decline in the study population. The FDA granted Fabhalta priority review for traditional approval in IgA nephropathy. For investors watching large pharma, Novartis sits at the intersection of immunology, allergy, and kidney...

The recent U.S. District Court order upholding a jury finding that Alcon (SWX:ALC) willfully infringed three Sight Sciences patents puts fresh attention on potential legal liabilities, ongoing Hydrus Microstent royalties, and appeal risk. See our latest analysis for Alcon. At a share price of CHF59.4, Alcon has a 1 day share price return of 0.58% and a 7 day share price return of 1.85%. However, a 1 year total shareholder return of 28.37% decline shows sentiment has cooled despite earlier...

PolyPeptide Group (SWX:PPGN) has expanded its credit facility to €200 million, bringing ING Bank into its lending group alongside UBS, Danske Bank and Zürcher Kantonalbank to support its revenue and capacity expansion objectives. See our latest analysis for PolyPeptide Group. That credit facility news arrives as momentum has been picking up, with the 7 day share price return of 8.54% and year to date share price return of 11.25% feeding into a 1 year total shareholder return of 62.61%. The...

If you are wondering whether UBS Group's current share price reflects its true value, focusing on what the numbers say rather than the headlines can help clarify the picture. The stock recently closed at CHF 29.38, with returns of 12.9% over 1 year and 70.6% over 3 years, alongside a 23.0% decline year to date and an 8.2% decline over the last 30 days. These moves may signal shifting expectations or risk perceptions. Recent coverage around UBS Group has highlighted its role as a global...

Wondering whether Nestlé at around CHF 76.37 is priced for quality, or leaving some value on the table for patient shareholders? The stock is up 0.7% over the last week, while the 30 day return is a 9.1% decline and the one year return is a 12.3% decline, which may change how you think about both upside and risk. Recent coverage has focused on Nestlé's position as a global consumer staples giant, its broad portfolio of food and beverage brands, and how that scale influences investor...